Day: August 5, 2021

Sydney, Aug. 05, 2021 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that the first patient has been enrolled and safely dosed in INSIGHT-003. This patient with metastatic non-small cell lung carcinoma received pembrolizumab plus doublet chemotherapy (carboplatin and pemetrexed) combined with Immutep’s lead product candidate eftilagimod alpha (efti or IMP321). INSIGHT-003 is evaluating a triple combination therapy consisting of efti in conjunction with an existing approved standard of care combination of chemotherapy and anti-PD-1 therapy. The study will continue to recruit up to 20 patients with various solid tumours and first results are expected in...

HTG Transcriptome Panel designed to measure approximately 20,000 mRNA targets using the HTG EdgeSeq technology Intended to serve as one of the technological cornerstones for the recently announced HTG Therapeutics Business Unit A third white paper highlighting the HTG Transcriptome Panel’s design, performance, and broad applicability now available TUCSON, Ariz., Aug. 05, 2021 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the commercial launch and immediate availability of its HTG Transcriptome Panel, designed to measure approximately 20,000 mRNA targets using the HTG EdgeSeq technology, in the U.S. and Europe. While HTG received its first orders for this product from Early Adopter Program (EAP) collaborators in June...

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the second quarter ended June 30, 2021, and provided a corporate update. “We continue to make progress in our complement and hemostasis programs. In complement, we are advancing the development of our SQ enhanced CFI development candidate, CB 4332, where we screened the first patient in our natural history study for CFI deficiency (“ConFIrm”). We also recently disclosed new proteases from our ProTUNE™; C3b-C4b degrader and ImmunoTUNE™; C3a-C5a degrader platforms designed to target specific disorders of the complement or inflammatory pathways,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. “With the initiation of the ConFIrm study and...

New Leadership, New Identity, New Company, New Partners DENVER, Aug. 05, 2021 (GLOBE NEWSWIRE) — authID.AI (www.authid.ai) [OTCQB:AUID] today announced its results for the second quarter ended June 30, 2021. The Company, previously known as Ipsidy, made strategic changes in its branding, leadership and board of directors, and continued to expand its channel partner network. The authID platform eliminates the need for passwords by delivering secure biometric identity proofing and authentication solutions to a broad array of verticals including finance, healthcare, sharing economy, online gaming and other large data-sensitive industries. The strengthened firm is poised to capture greater share of the growing market for password alternatives and cyber threat solutions. Financial Results for the Three Months and Six Months Ended June...

HOUSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) — IES Holdings, Inc. (or “IES” or the “Company”) (NASDAQ: IESC) today announced financial results for the quarter ended June 30, 2021. Third Quarter 2021 HighlightsRevenue of $406 million for the third quarter of fiscal 2021, an increase of 38% compared with $293 million for the same quarter of fiscal 2020 Operating income of $22.5 million for the third quarter of fiscal 2021, an increase of 60% compared with $14.1 million for the same quarter of fiscal 2020 Net income attributable to IES increased 57% to $19.3 million for the third quarter of fiscal 2021, compared with $12.3 million for the same quarter of fiscal 2020; diluted earnings per share attributable to common stockholders of $0.92 compared with $0.58 for the third fiscal quarters of 2021 and 2020, respectively Adjusted net income...

NORCROSS, Ga., Aug. 05, 2021 (GLOBE NEWSWIRE) — Intelligent Systems Corporation [NYSE: INS], the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, announced today its financial results for the quarter ended June 30, 2021. “Our strong momentum continued into the second quarter of fiscal 2021, led by CoreCard’s flexible and agile platform in a constantly shifting environment,” said Leland Strange, CEO of Intelligent Systems. “As expected, we recognized $2.3 million in license revenue, and the total revenue for the quarter increased 66% year-over-year to $13.4 million. Our substantial top-line growth more than offset higher costs associated with our infrastructure and platform investments and resulted in meaningful growth in income from operations and...

Current positive results with 3 variants, including alpha variant B.1.1.7 (“British” variant), beta variant B.1351 (“South African” variant) and gamma variant P.1 (“Brazilian” variant), follows prior pre-clinical tests indicating efficacy of the novel PARP inhibitor stenoparib against SARS-Cov-2Allarity Therapeutics is initiating further testing of stenoparib against delta variant B.1.617.2 (“Indian” variant)Press Release Hørsholm, Denmark (August 5, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced positive results from the further pre-clinical testing of the antiviral activity of its PARP inhibitor, stenoparib, against Coronavirus variant B.1.1.7 (British variant). The Pathogen and Microbiome Institute at Northern Arizona University (NAU), a leading U.S. infectious disease research center, conducted...

BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, August 12, 2021 at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2021, and to provide a clinical and corporate update. To access the live conference call, please dial (833) 301-1150 (domestic) or (914) 987-7391 (international) at least five minutes prior to the start time, and refer to conference ID 5795073. A live audio webcast of the call and accompanying slide presentation will be available in the Investors’ Events & Presentations section of the Company’s website, www.ateapharma.com. An archived webcast will be available on the Atea website approximately two hours...

Webcast and conference call for analysts and institutional investors MONTREAL, Aug. 05, 2021 (GLOBE NEWSWIRE) — Saputo Inc. (TSX:SAP) – Saputo Inc.’s Annual Meeting of Shareholders will be held in a virtual-only format on Thursday, August 5, 2021, at 10 a.m. (Eastern Time), via live webcast at: https://web.lumiagm.com/486765661. The speakers will be:Mr. Lino A. Saputo, Chair of the Board and Chief Executive Officer; Mr. Kai Bockmann, President and Chief Operating Officer, Saputo Inc. and International Sector; Mr. Maxime Therrien, Chief Financial Officer and Secretary.Fiscal 2022 First Quarter ResultsSaputo will release its fiscal 2022 first quarter financial results on Thursday, August 5, 2021. A webcast and conference call for analysts and institutional investors will follow at 1 p.m. (Eastern Time). The webcast will...